

EUROPEAN CURRICULUM
VITAE



PERSONAL INFORMATIONS

Name, Surname, Position
e-mail

Francesco Bertagna – MEDICAL DOCTOR- NUCLEAR MEDICINE SPECIALIST

francesco.bertagna@unibs.it

francesco.bertagna@asst-spedalicivili.it

Data of birth, place of birth

19/08/1977 - Brescia - Italy.

EDUCATION AND TRAINING

2002

MD graduation - University of Brescia Medical School - Italy. Thesis: "Left ventricular perfusion and function evaluation during myocardial infarction with GATED-SPECT. Clinical and functional correlation and 2 month follow-up".

2002- 2003;

2003

Internship Spedali Civili di Brescia.

2006

Nuclear Medicine Specialization - University of Brescia - Chair of Nuclear Medicine - 50/50 cum laude - Thesis: "¹⁸FDG-PET/CT evaluation in patients with differentiated thyroid carcinoma, negative iodine scan and high levels of thyroglobulin".

2006

Member of the Italian Association of Nuclear Medicine - AIMN

Attendance at conferences

Certificated attendance at 84 congresses.

Invited speaker at

36 congresses

PROFESSIONAL EXPERIENCES

2002

Progetto "PARTNER – Priorità di accesso e monitoraggio di prestazioni diagnostiche in cardiologia nucleare", commissionato da S.A.V.E. – Studi Analisi Valutazioni Economiche Sas – via Previati, 74 – 20149 Milano.

2006 to present

Staff Nuclear Medicine Division, Spedali Civili di Brescia.

December 2010 to 1/6/18

Assistant Professor, Chair of Nuclear Medicine, University of Brescia.

1/6/18 to present

Associate Professor Chair of Nuclear Medicine, University of Brescia.

2/10/18

Passed the National Scientific Qualification Exams for Full Professor.

RESEARCH

International Atomic energy
Agency (IAEA)

Investigator: **Coordinated research Project**: "Assessment of left ventricular function in coronary artery disease with nuclear techniques." CRP number: E1.30.34.

H10 EORTC/GELA/IIIL randomized
Intergroup trial

Participant: "**H10 EORTC/GELA/IIIL** randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined local treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma. Intergroup Study EORTC # 20051".

SPAG Protocol

Investigator : Multicentric study: **SPAG** (SPECT Attenuation Correction vs Gated).

90Y-DOTATOC

Investigator - phase IIA study: "**Protocollo clinico di fase II** di trattamento dei pazienti affetti da neoplasie neuroendocrine esprimenti i recettori per la somatostatina con **90Y-DOTATOC** . Protocol code: AOB-90YDOTATOC. EUDRACT: 2009-012754-20.

11C-choline PET/CT

Investigator Phase II study: " Protocollo sperimentale di valutazione della efficacia della **PET** con tracciante **11C-Choline** nella diagnostica della recidiva biochimica del carcinoma prostatico operato o radio trattato con intento radicale. Protocol code: AOB-CHOL-C11. EUDRACT:

	2009-013046-86.
ZETAL 07	“Due infusioni ripetute di Yttrium-90 Ibritumomab Tiuxetan (Zevalin) come trattamento di salvataggio in pazienti con linfoma aggressivo a cellule B recidivato e refrattario: studio di fase II. ZETAL07. Protocol code: ZETAL 07. EUDRACT: 2007-003539-22.
FIL_FOLL12	Partecipazione: Studio multicentrico, randomizzato di fase III per valutare l'efficacia di una strategia di mantenimento modulata sulla base della risposta al trattamento di induzione con chemioimmunoterapia standard in pazienti con Linfoma Follicolare in stadio avanzato. Studio ID: FIL_FOLL12 VERSIONE E DATA: VERSIONE 1.0 - 02 LUGLIO 2012 EUDRACT NUMBER: 2012-003170-60
INCAPS	INCAPS-The International Atomic Energy Agency (IAEA) Nuclear Cardiology Protocol Survey Study – Collaborator. A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma. EUDRACT number 2016-002794-35. A Randomized Double-Blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (CISPLATIN Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-Line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck. EUDRACT number 2016-001456-21
PUBLICATIONS	159 full text papers. 19 conference proceeding– first author. 45 conference proceeding – co-author. Current Radiopharmaceuticals Bentham Science; 2013-2014
Editorial Board Member	
FOREIGN LANGUAGES	
MOTHER TONGUE	ITALIAN
OTHER LANGUAGE	ENGLISH (READING AND WRITING: EXCELLENT; ORAL EXPRESSION: GOOD)

Date: 08 May 2019

Francesco Bertagna